Graduate Center, CUNY Researchers Link Overexpression of the MDMX Protein to Metastasis of Triple-Negative Breast Cancer
- Graduate Center, CUNY Researchers Link Overexpression of the MDMX Protein to Metastasis of Triple-Ne
New finding could potentially guide development of therapies that prevent this aggressive form of cancer from spreading beyond the breasts
NEW YORK, January 30, 2019 – The MDMX and MDM2 proteins play critical roles in keeping the tumor-suppressing protein p53 from damaging the production of healthy cells. But researchers have also found a causal connection between overexpression of MDMX and MDM2 and breast cancer. Now, in a newly published paper in the journal Breast Cancer Research, scientists at The Graduate Center of The City University of New York and Hunter College are the first to report that MDMX promotes metastasis of triple-negative breast cancer—one of the most aggressive forms of the disease, and one that is more prevalent in young women and women of color. The researchers also were able to duplicate early findings from other scientists who showed that MDM2 promotes metastasis of triple negative breast cancer.
“Triple-negative breast cancer metastasizes more often, so it’s one of most deadly forms of this disease,” said Graduate Center and Hunter College Professor Jill Bargonetti, whose lab conducted the research. “With this research, we now know that the MDMX protein may be one of the drivers that makes this form of cancer so aggressive, and we can potentially look at targeting this and the MDM2 protein to prevent these cancers from spreading.”
Caption: The MDMX and MDM2 proteins promote metastasis in triple-negative breast cancer, while the MDM2 protein promotes tumor growth in estrogen receptor a-positive breast cancer.
To collect response data on triple-negative breast cancer, Bargonetti’s team exposed mouse-model groups to cells with knocked-down MDMX or MDM2 genes. When researchers compared these groups to a mouse-model that received triple negative breast cancer cells expressing the two genes, they found a 96 percent reduction in circulation tumor cells (CTCs) in the mouse model that received the knocked-down MDMX cells and a 78 percent reduction in CTCs in mouse model that received the knocked-down MDM2 cells.
In a secondary experiment, the researchers also looked at the relationship between MDM2 and tumor growth in estrogen receptor positive breast cancer. For this work, they compared tumor size in a mouse model exposed to cells with knocked-down MDM2 and a mouse model without the knocked-down gene. They found that tumors grew at about half the rate in the knocked-down group.
The MDMX and MDM2 genes are expressed in multiple breast cancer subtypes. Determining these genes’ unique effect on tumor development and metastases in various types of cancer could help researchers identify new drug targets, novel therapies and create more precise treatment regimens. Bargonetti and her team are considering next steps for advancing their findings towards potential drug development. “These studies are very expensive, but our next goal would be to test one of the small molecules known to block MDMX to see if it can inhibit metastases,” she said.
Submitted on: JAN 30, 2019
Category: General GC News | Press Room | Research Studies